This study aims to test a new drug, remternetug, for treating people at risk of early-onset Alzheimer's disease (AD) due to genetics. Alzheimer's disease is a condition that affects the brain, causing memory loss and other thinking problems as people age. In this study, researchers are looking to see if the drug can prevent or slow the buildup of a protein called amyloid beta (Aβ) in the brain, which is believed to play a key role in AD.

The study is divided into two stages. Stage 1 checks if remternetug can stop or reduce Aβ accumulation. Stage 2 looks at the effects of early treatment on other disease indicators compared to control groups. Participants will undergo brain scans and blood tests to track changes.

• Participants must be asymptomatic carriers of AD-related gene mutations.
• The study involves regular visits for assessments and tests.
• Potential benefits include slowing disease progression before symptoms appear.

Participants need to be at least 18 years old, fluent in the trial's language, and have a study partner. They must also meet specific health criteria and not have certain medical conditions.